Investigational Drug Information for AZD5718
✉ Email this page to a colleague
What is the drug development status for AZD5718?
AZD5718 is an investigational drug.
There have been 13 clinical trials for AZD5718.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 30th 2017.
The most common disease conditions in clinical trials are Coronary Artery Disease, Coronary Disease, and Myocardial Ischemia. The leading clinical trial sponsors are AstraZeneca, Parexel, and Quotient Sciences.
There are seven US patents protecting this investigational drug and sixty-six international patents.
Summary for AZD5718
| US Patents | 7 |
| International Patents | 66 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2017-10-30) |
| Vendors | 30 |
Recent Clinical Trials for AZD5718
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess the Efficacy and Safety of AZD5718 in Moderate-to-Severe Uncontrolled Asthma | AstraZeneca | Phase 2 |
| Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers | Parexel | Phase 1 |
| Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers | AstraZeneca | Phase 1 |
Clinical Trial Summary for AZD5718
Top disease conditions for AZD5718
Top clinical trial sponsors for AZD5718
US Patents for AZD5718
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AZD5718 | ⤷ Start Trial | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Start Trial |
| AZD5718 | ⤷ Start Trial | Pyrazole derivatives useful as 5-lipdxygenase activating protein (FLAP) inhibitors | ASTRAZENECA AB (Sodertalje, SE) | ⤷ Start Trial |
| AZD5718 | ⤷ Start Trial | Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahyd- ropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide | AstraZeneca AB (Sodertalje, SE) | ⤷ Start Trial |
| AZD5718 | ⤷ Start Trial | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | AstraZeneca AB | ⤷ Start Trial |
| AZD5718 | ⤷ Start Trial | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | Gilead Sciences Inc | ⤷ Start Trial |
| AZD5718 | ⤷ Start Trial | Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors | AstraZeneca AB | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AZD5718
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AZD5718 | Argentina | AR104512 | 2035-05-04 | ⤷ Start Trial |
| AZD5718 | Australia | AU2016258874 | 2035-05-04 | ⤷ Start Trial |
| AZD5718 | Brazil | BR112017022757 | 2035-05-04 | ⤷ Start Trial |
| AZD5718 | Canada | CA2983668 | 2035-05-04 | ⤷ Start Trial |
| AZD5718 | Chile | CL2017002660 | 2035-05-04 | ⤷ Start Trial |
| AZD5718 | China | CN107646036 | 2035-05-04 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
